Aura Biosciences (AURA) Stock Price, News & Analysis

Company Overview

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $6.30 to $6.89
• 50-Day Range: $5.84 to $7.23
• 52-Week Range: $4.34 to $12.38
• Volume: 126,672 shs
• Average Volume: 164,544 shs
• Market Capitalization: $329.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.00
• Consensus Rating: Buy

Aura Biosciences Stock Analysis - MarketRank™

Aura Biosciences scored higher than 39% of companies evaluated by MarketBeat, and ranked 654th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Aura Biosciences has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aura Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Aura Biosciences are expected to decrease in the coming year, from ($1.66) to ($2.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aura Biosciences is -3.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aura Biosciences is -3.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aura Biosciences has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.82% of the float of Aura Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Aura Biosciences has a short interest ratio ("days to cover") of 12.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Aura Biosciences has recently increased by 1.50%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aura Biosciences does not currently pay a dividend.

Dividend Growth

Aura Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.82% of the float of Aura Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Aura Biosciences has a short interest ratio ("days to cover") of 12.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Aura Biosciences has recently increased by 1.50%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.84

News Sentiment

Aura Biosciences has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Aura Biosciences this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for AURA on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Aura Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Aura Biosciences insiders have bought 4,284.51% more of their company's stock than they have sold. Specifically, they have bought $343,000.00 in company stock and sold $7,823.00 in company stock.

Percentage Held by Insiders

Only 5.40% of the stock of Aura Biosciences is held by insiders.

Percentage Held by Institutions

96.75% of the stock of Aura Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AURA Stock Analysis - Frequently Asked Questions

How have AURA shares performed this year?

Aura Biosciences' stock was trading at $8.22 at the start of the year. Since then, AURA shares have decreased by 20.3% and is now trading at $6.55.

How were Aura Biosciences' earnings last quarter?

Aura Biosciences, Inc. (NASDAQ:AURA) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by $0.08.

When did Aura Biosciences IPO?

Aura Biosciences (AURA) raised $81 million in an IPO on Friday, October 29th 2021. The company issued 5,400,000 shares at a price of $14.00-$16.00 per share.

Who are Aura Biosciences' major shareholders?

Aura Biosciences' top institutional shareholders include Levin Capital Strategies L.P. (2.98%), Regency Capital Management Inc. DE (1.32%), Platinum Investment Management Ltd. (0.27%) and Harbor Capital Advisors Inc. (0.07%). Insiders that own company stock include Matrix Capital Management Comp, Los Pinos Elisabet De, Janet Jill Hopkins, Mark Plavsic, Conor Kilroy, David Michael Johnson, Julie B Feder, Amy Elazzouzi, Anthony S Gibney, Cadmus Rich and Rosch Mark De.
View institutional ownership trends.

How do I buy shares of Aura Biosciences?

Shares of AURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aura Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aura Biosciences investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 8/07/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AURA
• CIK: 1501796
• Web: www.aurabiosciences.com
• Phone: 617-500-8864
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Aura Biosciences: $22.00
• High Price Target: $24.00
• Low Price Target: $19.00
• Potential Upside/Downside: +235.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$86.92 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -58.63%
• Return on Assets: -49.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.06
• Quick Ratio: 11.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.04 per share
• Price / Book: 2.15

Miscellaneous

• Outstanding Shares: 50,270,000
• Free Float: 47,554,000
• Market Cap: $329.27 million
• Optionable: Not Optionable
• Beta: 0.46